Recombinant human thyrotropin in veterinary medicine: current use and future perspectives.

IF 2.6 2区农林科学

Journal of Veterinary Internal Medicine Pub Date : 2012-07-01 Epub Date: 2012-06-07 DOI:10.1111/j.1939-1676.2012.00950.x

M Campos, I van Hoek, K Peremans, S Daminet

{"title":"Recombinant human thyrotropin in veterinary medicine: current use and future perspectives.","authors":"M Campos, I van Hoek, K Peremans, S Daminet","doi":"10.1111/j.1939-1676.2012.00950.x","DOIUrl":null,"url":null,"abstract":"<p><p>Recombinant human thyrotropin (rhTSH) was developed after bovine thyrotropin (bTSH) was no longer commercially available. It was approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) as an aid to diagnostic follow-up of differentiated thyroid carcinoma in humans and for thyroid remnant ablation with radioiodine. In addition, rhTSH is used in human medicine to evaluate thyroid reserve capacity and to enhance radioiodine uptake in patients with metastatic thyroid cancer and multinodular goiter. Likewise, rhTSH has been used in veterinary medicine over the last decade. The most important veterinary use of rhTSH is thyroidal functional reserve testing for the diagnosis of canine hypothyroidism. Recent pilot studies performed at Ghent University in Belgium have investigated the use of rhTSH to optimize radioiodine treatment of canine thyroid carcinoma and feline hyperthyroidism. Radioiodine treatment optimization may allow a decreased therapeutic dosage of radioiodine and thus may improve radioprotection. This review outlines the current uses of rhTSH in human and veterinary medicine, emphasizing research performed in dogs and cats, as well as potential future applications.</p>","PeriodicalId":17462,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2012-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1939-1676.2012.00950.x","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/j.1939-1676.2012.00950.x","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/6/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Recombinant human thyrotropin (rhTSH) was developed after bovine thyrotropin (bTSH) was no longer commercially available. It was approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) as an aid to diagnostic follow-up of differentiated thyroid carcinoma in humans and for thyroid remnant ablation with radioiodine. In addition, rhTSH is used in human medicine to evaluate thyroid reserve capacity and to enhance radioiodine uptake in patients with metastatic thyroid cancer and multinodular goiter. Likewise, rhTSH has been used in veterinary medicine over the last decade. The most important veterinary use of rhTSH is thyroidal functional reserve testing for the diagnosis of canine hypothyroidism. Recent pilot studies performed at Ghent University in Belgium have investigated the use of rhTSH to optimize radioiodine treatment of canine thyroid carcinoma and feline hyperthyroidism. Radioiodine treatment optimization may allow a decreased therapeutic dosage of radioiodine and thus may improve radioprotection. This review outlines the current uses of rhTSH in human and veterinary medicine, emphasizing research performed in dogs and cats, as well as potential future applications.

查看原文本刊更多论文

重组人促甲状腺素在兽药中的应用现状及展望。

重组人促甲状腺素(rhTSH)是在牛促甲状腺素(bTSH)不再市售后开发的。它已被美国食品和药物管理局(FDA)和欧洲药品管理局(EMEA)批准用于人类分化性甲状腺癌的诊断随访和放射性碘残留甲状腺消融。此外，rhTSH在人类医学中用于评估甲状腺储备能力，并增强转移性甲状腺癌和多结节性甲状腺肿患者的放射性碘摄取。同样，rhTSH在过去十年中也被用于兽药。rhTSH最重要的兽医应用是甲状腺功能储备测试诊断犬甲状腺功能减退症。最近在比利时根特大学进行的试点研究调查了使用rhTSH优化犬甲状腺癌和猫甲状腺功能亢进的放射性碘治疗。放射性碘治疗的优化可以降低放射性碘的治疗剂量，从而可以改善放射性防护。本文概述了rhTSH目前在人类和兽药中的应用，强调了在狗和猫身上进行的研究，以及潜在的未来应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Veterinary Internal Medicine Veterinary-General Veterinary

自引率

11.50%

发文量

243

期刊介绍： The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.